CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI) in a research report sent to investors on Tuesday. The firm issued a hold rating on the biotechnology company’s stock.

CASI Pharmaceuticals Trading Down 3.3 %

Shares of CASI opened at $2.66 on Tuesday. CASI Pharmaceuticals has a twelve month low of $1.85 and a twelve month high of $8.48. The stock has a market cap of $35.65 million, a PE ratio of -1.32 and a beta of 0.41. The company has a quick ratio of 2.60, a current ratio of 3.55 and a debt-to-equity ratio of 0.78. The business’s 50-day moving average price is $3.35 and its 200-day moving average price is $4.90.

CASI Pharmaceuticals (NASDAQ:CASI) last issued its quarterly earnings data on Thursday, March 28th. The biotechnology company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.05). CASI Pharmaceuticals had a negative net margin of 79.30% and a negative return on equity of 77.55%. The firm had revenue of $6.03 million for the quarter, compared to analysts’ expectations of $9.40 million.

Institutional Investors Weigh In On CASI Pharmaceuticals

An institutional investor recently bought a new position in CASI Pharmaceuticals stock. Howland Capital Management LLC bought a new position in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 40,429 shares of the biotechnology company’s stock, valued at approximately $146,000. Howland Capital Management LLC owned about 0.30% of CASI Pharmaceuticals as of its most recent SEC filing. 22.23% of the stock is currently owned by hedge funds and other institutional investors.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.